Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.

07-Sep-2009 - USA

Intendis GmbH, which is part of Bayer HealthCare, announced that it has signed an agreement to acquire two prescription dermatology product lines from SkinMedica, Inc.

Both Desonate® and NeoBenz® Micro are currently marketed in the U.S. by SkinMedica, Inc. Under the transaction, which is still subject to the necessary regulatory approvals, Intendis will acquire all commercial rights, including assigned contracts and intellectual property related to the two product lines. The deal is expected to close in the Fall of 2009.

“We are currently seeing solid growth of our existing portfolio of prescription dermatologicals in the U.S. With the addition of these two high-quality product lines we expect to build on this dynamic and to substantially strengthen our presence in this key strategic business,” stated Marc Lafeuille, President and CEO of the Intendis Group. In 2008, the company grew by 18.7% on a currency-adjusted basis in the U.S.

Desonate® is a low potency topical corticosteroid for the treatment of mild to moderate atopic dermatitis, an inflammatory skin disease. Formulated in a waterbased Hydrogel vehicle, it is indicated for patients as young as 3 months. NeoBenz® Micro is a benzoyl peroxide medication for the treatment of mild to moderate acne vulgaris. Its special formulation allows for a gradual release of the active ingredient which allows for an effective treatment with only low irritation.

https://www.bionity.com/en/news/105887/bayer-acquires-two-prescription-dermatology-product-lines-from-skinmedica-in-the-u-s.html